Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Nevus, Sebaceous of Jadassohn 2Oncogenic osteomalacia 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × burosumab × Clear all
NCT02304367 2024-05-06

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
17 enrolled 66 charts

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT04320316 2022-10-07

ENS

University of Alabama at Birmingham

Phase 4 Completed
1 enrolled 10 charts

Nevus, Sebaceous of Jadassohn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡